NASDAQ:TNGX • US87583X1090
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for TANGO THERAPEUTICS INC (TNGX).
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2026-03-11 | Mizuho | Maintains | Outperform -> Outperform |
| 2026-03-09 | Stifel | Maintains | Buy -> Buy |
| 2026-03-06 | Guggenheim | Maintains | Buy -> Buy |
| 2026-03-06 | Wedbush | Maintains | Outperform -> Outperform |
| 2026-03-06 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2026-02-23 | Mizuho | Initiate | Outperform |
| 2026-02-06 | Guggenheim | Maintains | Buy -> Buy |
| 2026-01-16 | Piper Sandler | Maintains | Overweight -> Overweight |
| 2025-12-04 | Stifel | Initiate | Buy |
| 2025-11-18 | Wolfe Research | Initiate | Peer Perform |
| 2025-11-18 | B. Riley Securities | Maintains | Buy -> Buy |
| 2025-10-24 | Guggenheim | Maintains | Buy -> Buy |
| 2025-08-19 | Piper Sandler | Initiate | Overweight |
| 2025-08-06 | Guggenheim | Maintains | Buy -> Buy |
| 2025-04-14 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-12-05 | Cantor Fitzgerald | Reiterate | Overweight -> Overweight |
| 2024-11-11 | B. Riley Securities | Maintains | Buy -> Buy |
| 2024-11-08 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-11-07 | Guggenheim | Maintains | Buy -> Buy |
| 2024-10-28 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-09-10 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-08-08 | Wedbush | Maintains | Outperform -> Outperform |
| 2024-07-17 | Jefferies | Initiate | Buy |
| 2024-07-09 | Cantor Fitzgerald | Reiterate | Overweight |
| 2024-07-09 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 36.527M 46.93% | 42.069M 15.17% | 62.384M 48.29% | -100.00% | 36.347M | 203.79M 460.68% | 486.32M 138.64% | 801.55M 64.82% | 1.056B 31.74% | 1.25B 18.37% | ||
| EBITDA YoY % growth | -111.758M -2.10% | -143.096M -28.04% | -109.008M 23.82% | -200.695M -84.11% | -218.413M -8.83% | N/A | -163.894M | -10.771M 93.43% | 112.01M 1,139.90% | 238.49M 112.92% | 380.38M 59.50% | |
| EBIT YoY % growth | -114.173M -2.79% | -145.595M -27.52% | -111.289M 23.56% | -194.666M -74.92% | -236.379M -21.43% | -272.726M -15.38% | -151.296M 44.52% | 40.23M 126.59% | 304.41M 656.67% | 603.9M 98.38% | 819.78M 35.75% | |
| Operating Margin | -312.57% | -346.09% | -178.39% | N/A | N/A | -750.34% | -74.24% | 8.27% | 37.98% | 57.19% | 65.58% | |
| EPS YoY % growth | -1.10 10.57% | -1.21 -10.00% | -0.86 28.93% | -1.28 -48.58% | -1.43 -11.76% | -1.19 16.43% | -0.95 20.68% | 0.21 121.98% | 1.96 839.56% | 2.58 32.17% | 2.96 14.74% |
All data in USD
| Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | |
|---|---|---|---|---|
| EPS Q2Q % growth | -0.31 13.30% | -0.31 11.60% | -0.32 -331.93% | -0.33 -13.14% |
| Revenue Q2Q % growth | -100.00% | -100.00% | -100.00% | |
| EBITDA Q2Q % growth | -45.155M -7.75% | -49.96M -25.78% | -51.031M -421.47% | -51.673M -30.54% |
| EBIT Q2Q % growth | -45.21M -6.30% | -47.598M -16.19% | -48.848M -447.13% | -50.016M -19.47% |
All data in USD
17 analysts have analysed TNGX and the average price target is 15.19 USD. This implies a price decrease of -21.15% is expected in the next year compared to the current price of 19.26.
TANGO THERAPEUTICS INC (TNGX) will report earnings on 2026-05-11.
The consensus EPS estimate for the next earnings of TANGO THERAPEUTICS INC (TNGX) is -0.31 USD and the consensus revenue estimate is 0 USD.
The consensus rating for TANGO THERAPEUTICS INC (TNGX) is 85.8824 / 100 . This indicates that analysts generally have a positive outlook on the stock.